Policy
Latest News
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025
A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
More News
Healthcare Costs and Nonadherence Among Chronic Opioid Users
Harry L. Leider, MD, MBA;Jatinder Dhaliwal, MBA;Elizabeth J. Davis, PhD;Mahesh Kulakodlu, MS;Ami R. Buikema, MPH
January 25th 2011Healthcare costs are elevated for patients on chronic opioid therapy; nonadherence to the opioid regimen, based on urine drug monitoring results, further increases costs.
Read More
